News
GSK and MMV initiate Phase III programme for development of malaria drug
GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) have initiated a Phase III global programme to assess the efficacy and safety of tafenoquine, an investigational medicine, being developed for the treatment and relapse prevention (radical cure) of Plasmodium vivax...
News
Ohr Pharma completes patient enrolment in Phase II trial of macular degeneration drug
US-based Ohr Pharmaceutical has completed patient enrolment in its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for treatment of the wet form of age related macular degeneration (wet-AMD). A total of 142 treatment naive...
News
Janssen’s type 2 diabetes drug Vokanamet gets European Commission approval in EU
Janssen-Cilag International (Janssen) has received approval from the European Commission (EC) for use of Vokanamet in the European Union (EU) as a treatment for adults with type 2 diabetes mellitus to improve glycaemic control. Vokanamet is...
News
Bavarian Nordic doses first patient in Phase II trial of CV-301 to treat bladder cancer
Denmark-based biotechnology firm Bavarian Nordic has dosed first patient in a randomised, prospective Phase II trial of its active immunotherapy product candidate CV-301 for treatment of bladder cancer. In the trial, which is sponsored by the...
News
NICE recommends afatinib for treatment of lung cancer
The National Institute for Health and Care Excellence (NICE) in the UK has issued its final health technology appraisal recommending afatinib as a first-line treatment option for patients with advanced or metastatic non-small cell lung cancer (NSCLC). ...
News
Pfizer confirms £60bn bid interest in AstraZeneca
US-based drug maker Pfizer has confirmed that it has contacted AstraZeneca seeking to renew discussions over a possible £60bn takeover. The discussions are regarding developing a proposal by both companies that could be recommended to their...
News
Alexion begins multinational registration trials of eculizumab to treat NMO and MG
US-based Alexion Pharmaceuticals has started a single, multinational, placebo-controlled trial designed to assess the safety and efficacy of eculizumab (Soliris) in patients with relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. Primary objective of the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read